The 2024 Trends Shaping the Health Economy report gave a past, present, and future look at diabetes care in the US and the ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Why a Malvern biopharma is exploring combining its lead drug candidate targeting Alzheimer's and Parkinson's diseases with a ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Two naturally occurring molecules could be the key to sustained weight management, offering an organic alternative to ...

We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, we are going to take a look ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

People who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be way less likely to die from ...

Zmyra has become a standout natural alternative to Ozempic for weight loss. Reviewers for this article believe it to be the ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...